Regeneron announces FDA approval for anti-VEGF Eylea to treat macular edema following CRVO
Regenerom Pharmaceuticals Inc (REGN, Tarrytown, New York) have announced the receipt of FDA approval for their VEGF trap eye product for the treatment of macular edema following central retinal vein occlusion.

To know more please click here.

Overview